WSR 05-11-078

PERMANENT RULES

DEPARTMENT OF

SOCIAL AND HEALTH SERVICES
(Medical Assistance Administration)

[ Filed May 17, 2005, 4:39 p.m. , effective June 17, 2005 ]


     

     Purpose: To correct a typographical error in a cross-reference. The introduction to WAC 388-530-1280 refers to RCW 69.41.090; the correct reference is RCW 69.41.190.

     Citation of Existing Rules Affected by this Order: Amending WAC 388-530-1280.

     Statutory Authority for Adoption: RCW 69.41.190, 70.14.050, and 74.08.090.

      Adopted under notice filed as WSR 05-06-095 on March 1, 2005.

     Number of Sections Adopted in Order to Comply with Federal Statute: New 0, Amended 0, Repealed 0; Federal Rules or Standards: New 0, Amended 0, Repealed 0; or Recently Enacted State Statutes: New 0, Amended 0, Repealed 0.

     Number of Sections Adopted at Request of a Nongovernmental Entity: New 0, Amended 0, Repealed 0.

     Number of Sections Adopted on the Agency's Own Initiative: New 0, Amended 0, Repealed 0.

     Number of Sections Adopted in Order to Clarify, Streamline, or Reform Agency Procedures: New 0, Amended 1, Repealed 0.

     Number of Sections Adopted Using Negotiated Rule Making: New 0, Amended 0, Repealed 0;      Pilot Rule Making: New 0, Amended 0, Repealed 0; or Other Alternative Rule Making: New 0, Amended 1, Repealed 0.

     Date Adopted: May 10, 2005.

Andy Fernando, Manager

Rules and Policies Assistance Unit

3519.2
AMENDATORY SECTION(Amending WSR 05-02-044, filed 12/30/04, effective 1/30/05)

WAC 388-530-1280   Preferred drug list(s).   This section contains the medical assistance administration's (MAA) rules for preferred drug list(s) (PDL). Under RCW ((69.41.090)) 69.41.190 and 70.14.050, MAA and other state agencies cooperate in developing and maintaining preferred drug list(s).

     (1) The Washington preferred drug list (PDL):

     (a) Washington state contracts with evidence-based practice center(s) for systematic reviews of drug(s).

     (b) The pharmacy and therapeutics (P&T) committee reviews and evaluates the safety, efficacy, and outcomes of prescribed drugs, using evidence-based information provided by the evidence-based practice center(s).

     (c) The P&T committee makes recommendations to state agencies as to which drug(s) to include on the Washington PDL, under chapter 182-50 WAC.

     (d) The appointing authority makes the final selection of drugs included on the Washington PDL.

     (e) Nonpreferred drugs within a therapeutic class on the Washington PDL are subject to the therapeutic interchange program (TIP) according to WAC 388-530-1290.

     (2) The medical assistance administration's (MAA's) PDL. Drugs on MAA's PDL:

     (a) Are not part of the Washington PDL;

     (b) Are not subject to TIP; and

     (c) Continue to require prior authorization when they are designated as nonpreferred.

     (3) Combination drugs that are not on the Washington PDL, that are not reviewed by the evidence-based practice center(s), and that are not subject to TIP under WAC 388-530-1290, are considered for coverage according to MAA's prior authorization program.

[Statutory Authority: RCW 74.08.090, 70.14.050, 69.41.150, 69.41.190, chapter 41.05 RCW. 05-02-044, § 388-530-1280, filed 12/30/04, effective 1/30/05.]

© Washington State Code Reviser's Office